Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RP912
- Development stage
- Preclinical
- Lead developer
- Risen
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
RP912 is an investigational small interfering RNA (siRNA) therapeutic developed by Risen Biosci (Risen Pharma) in collaboration with Junshi Biosciences (TopAlliance). The drug is designed to target and silence the mRNA encoding angiopoietin-like 3 (ANGPTL3), a protein primarily synthesized in the liver that acts as a key regulator of lipid metabolism. ANGPTL3 typically inhibits lipoprotein lipase and endothelial lipase; therefore, by reducing its expression, RP912 facilitates the clearance of triglycerides and low-density lipoprotein cholesterol (LDL-C) from the bloodstream. This therapeutic approach is intended for the treatment of metabolic diseases, specifically dyslipidemia and hypercholesterolemia. As of the current pipeline status, RP912 is in the IND-enabling stage of development.
- Other names
- ANGPTL3-siRNAANGPTL-3-siRNAANGPTL 3-siRNARisen ANGPTL3 siRNA
02
Targets
ANGPTL3 (Angiopoietin-like protein 3)
Beyond the preview
Go deeper on RP912.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RP912.